Diagnostics consultation workshopStart Date 19/06/2017 End Date 19/06/2017
Diagnostics for reducing antimicrobial resistance (AMR)
The Innovative Medicines Initiative (IMI), in collaboration with major European diagnostics companies and the Wellcome Trust, held a consultation workshop to discuss 'Diagnostics for reducing antimicrobial resistance (AMR)' on 19 June 2017 in Brussels, Belgium.
The goals of the workshop were:
- To consult with the relevant stakeholders on a potential Call for proposals under IMI2 addressing the topic 'Diagnostics for reducing AMR' that would aim at establishing a framework for value-based translation of innovative diagnostics into routine use to reduce AMR.
- To better understand the challenges and hurdles faced by diagnostic innovators for translation of early-stage products into validation, and value demonstration in primary and clinical healthcare practice.
- To obtain a better understanding of what evidence is needed from regulators, health technology assessment bodies and payers for implementation and adoption by healthcare systems.
It is expected that the discussions and conclusions of the consultation workshop will feed into a future IMI2 Call for proposals topic.
- Pre-reads: this document has been prepared to allow all participants to familiarise themselves with the topics ahead of the workshop
- Meeting report
- Attendance list
Session 1: Welcome & setting the scene
The Innovative Medicines Initiative: building new models of collaborative research
Angela Wittelsberger, Innovative Medicines Initiative
Diagnostics to address antimicrobial resistance
Mark Miller, bioMérieux
The Wellcome Trust’s view on in vitro diagnostics for addressing antimicrobial resistance
Timothy Jinks, Wellcome Trust Drug Resistant Infections priority program
The European Commission’s view on in vitro diagnostics for addressing antimicrobial resistance
Arjon Van Hengel, DG Research & Innovation, European Commission
Session 2: Presentation of preliminary plans for a topic under the Innovative Medicines Initiative ‘Diagnostics in AMR’
Implementation of diagnostics
Volker Liebenberg, Thermo Fisher
Where are the gaps towards a standardised care network?
Philippe Cleuziat, bioMérieux
Design of a clinical study to demonstrate the value of diagnostics
Kieran Clarke, Alere